Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

TVGN·NASDAQ

$0.25

-5.8%
HealthcareBiotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

At a Glance

Live Snapshot
Market Cap$50.14M
EPS-0.0936
P/E Ratio-14.94
Earnings Date03/25/2026

No Dividend Yield Data

TVGN has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

TVGN has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

TVGN has not reported any net dividends paid values in the available annual periods.

Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. Dividend History

TVGN · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

TVGN Dividend Payment History

TVGN · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
tvgn

Tevogen Bio Holdings Inc. Payout Ratio Analysis

TVGN · NASDAQ
Dividends Paid
0.00
2024
Net Income
-10.11M
2024
Payout Ratio
0.00%
2024

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.